ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $2.09M, a 109907% increase year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $2.09M +$2.09M +109907% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $2.22M +$2.21M +29419% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $2.36M +$2.34M +17931% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 $26.2K +$7.73K +41.8% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $1.9K -$22K -92% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $7.53K -$973K -99.2% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $13.1K -$1.02M -98.7% Mar 31, 2023 10-K 2024-07-01
Q4 2022 $18.5K -$1.06M -98.3% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 $23.9K -$1.12M -97.9% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $981K -$219K -18.3% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $1.03M +$817K +381% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $1.08M +$870K +410% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $1.14M +$878K +333% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $1.2M +$886K +282% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $215K -$149K -40.9% Mar 31, 2021 10-K 2022-06-29
Q4 2020 $212K -$200K -48.5% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $263K -$197K -42.7% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $314K -$194K -38.2% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $363K -$191K -34.4% Mar 31, 2020 10-K 2021-06-14
Q4 2019 $412K Dec 31, 2019 10-Q 2020-02-10
Q3 2019 $460K Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $507K Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $554K Apr 2, 2019 10-Q 2019-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.